Trial Profile
A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Crenigacestat (Primary)
- Indications Adenoid cystic carcinoma; B-cell lymphoma; Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lymphoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Apr 2019 Results (n=22) of expansion cohort of patients with advanced or metastatic adenoid cystic carcinoma published in the Investigational New Drugs
- 12 Sep 2018 Results published in the European Journal of Cancer.
- 06 Aug 2018 Status changed from active, no longer recruiting to completed.